2. Results of trial group analyses for overall survival (Main group of 13 trials only).
HR(95%CI) | Interaction p‐value | |
Planned Chemotherapy type Platinum based Non‐platinum based |
0.84 (0.72‐0.98) 0.76 (0.62‐0.94) | 0.48 |
Planned Radiotherapy dose > 45 Gy + BRT < 45 Gy + BRT |
0.78 (0.68‐0.89) 0.93 (0.70‐1.24) |
0.26 |
Planned Radiotherapy duration < 8 weeks > 8 weeks |
0.83 (0.72‐0.96) 0.73 (0.57‐0.93) | 0.35 |
Planned chemotherapy cycle length < 1 week > 1 week |
0.74 (0.60‐0.92) 0.95 (0.72‐1.25) |
0.16 |
Planned Cisplatin dose intensity < 25mg/m2/week > 25mg/m2/week |
0.93 (0.70‐1.24) 0.76 (0.62‐0.96) | 0.25 |
Cisplatin regimen Single‐agent Combination | 0.76 (0.62‐0.93) 0.93 (0.70‐1.24) | 0.25 |
Chemotherapy regimen Single agent Combination |
0.75 (0.63‐0.88) 0.86 (0.71‐1.04) | 0.29 |